RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257237
DO 10.1101/2021.05.19.21257237
A1 Magalis, Brittany Rife
A1 Mavian, Carla
A1 Tagliamonte, Massimiliano
A1 Rich, Shannan N.
A1 Cash, Melanie
A1 Riva, Alberto
A1 Loeb, Julia C.
A1 Norris, Michael
A1 Amador, David Moraga
A1 Zhang, Yanping
A1 Shapiro, Jerne
A1 Starostik, Petr
A1 Marini, Simone
A1 Myers, Paul
A1 Ostrov, David
A1 Lednicky, John A.
A1 Glenn Morris, J. John
A1 Lauzardo, Michael
A1 Salemi, Marco
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.05.19.21257237.abstract
AB The emergence of SARS-CoV-2 variants of concern (VOC) has raised questions regarding the extent of protection of currently implemented vaccines. Ten “vaccination breakthrough” infections were identified in Alachua County, Florida, among individuals fully vaccinated with the BNT162b2 mRNA vaccine as a result of social or household transmission. Eight individuals presented mild symptoms in the absence of infection with other common respiratory viruses, confirmed using viral genetic sequencing. SARS-CoV-2 genomes were successfully generated for five of the vaccine breakthroughs and 399 individuals in the surrounding area and were included for reference-based phylogenetic investigation. These five individuals were characterized by infection with both VOCs and low-frequency variants present within the surrounding population. Mutations, in the Spike glycoprotein, were consistent with their respective circulating lineages. However, we detected an additional mutation in Spike’s N-terminal domain of a B.1.1.7 strain, present at low-frequency (∼1%) in the unvaccinated population, potentially affecting protein’s stability and functionality. The findings highlight the critical need for continued testing and monitoring of infection among individuals regardless of vaccination status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Stephany W. Holloway University of Florida Chair and by funds of the University of Florida Office of Research and Health Science Center .Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by UF IRB: IRB202000633 has been ApprovedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGISAID sequences used for the study are described in the Supplementary Material. Newly added sequences will be submitted to GISAID following acceptance but are available from the authors (along with sequence quality information) until such time.